GlassScriptPhysician profile
Walter L Fletscher
NPI 1407879901
$3,577.00
in general payments reported to CMS, 2019-2025
26 companies · $299 in 2025
The $299 reported for 2025 was less than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $567 · 2020: $628 · 2021: $613 · 2022: $560 · 2023: $514 · 2024: $397 · 2025: $299.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,210.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,209.82 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $970.40 | 2019-2025 | Jot Dx, Aveir, Merlin@Home |
| Amgen INC. | $363.59 | 2019-2023 | Repatha |
| Janssen Pharmaceuticals, INC | $334.60 | 2019-2023 | Xarelto |
| Amarin Pharma, INC. | $273.51 | 2019-2021 | |
| Novartis Pharmaceuticals Corporation | $264.65 | 2019-2024 | |
| Merck Sharp & Dohme LLC | $204.69 | 2021-2024 | Verquvo |
| Boehringer Ingelheim Pharmaceuticals, INC. | $169.10 | 2021-2024 | Jardiance |
| Alnylam Pharmaceuticals INC. | $141.26 | 2023-2025 | Amvuttra, Onpattro |
| Astrazeneca Pharmaceuticals LP | $117.11 | 2020-2023 | Farxiga |
| E.R. Squibb & Sons, L.L.C. | $88.19 | 2019-2024 | Eliquis |
| Daiichi Sankyo INC. | $74.14 | 2023-2024 | Injectafer |
| Sanofi-Aventis U.S. LLC | $72.89 | 2021-2022 | |
| Kiniksa Pharmaceuticals, LTD. | $64.68 | 2021-2023 | Arcalyst |
| Novo Nordisk INC | $55.37 | 2025 | Wegovy |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $50.35 | 2025 | Lifevest |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Chiesi USA, INC. | $48.75 | 2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $42.95 | 2025 | |
| Pfizer INC. | $39.98 | 2020-2021 | |
| Philips North America LLC | $36.94 | 2024 | (Cm9) Amb Mon & Diag Und |
| Baxter Healthcare | $36.24 | 2023 | Hillrom - Cardiac Ambulatory Monitor |
| Arbor Pharmaceuticals, INC. | $33.48 | 2021 | |
| Kiniksa Pharmaceuticals International, Plc | $27.36 | 2024 | Arcalyst |
| Sun Pharmaceutical Industries INC. | $21.00 | 2021 | |
| Actelion Pharmaceuticals US, INC. | $20.57 | 2023 | Uptravi, Opsumit |
| Heartflow, INC. | $12.95 | 2022 | |
| Bardy Diagnostics, INC. | $12.25 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Walter Fletscher listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.